Scientists have discovered a potential reason why melanoma doesn’t always respond to certain drugs.
For some advanced melanoma patients, immune checkpoint inhibitors — a kind of immunotherapy that pushes the immune system to attack tumors — can lead to long-term remission. But for many patients, the drugs don’t work. Now, scientists at Swiss Federal Institute of Technology in Lausanne studying a mouse model of melanoma have discovered that “bad immune cells” might be limiting how well the drugs work. Their findings were published this week in Science Translational Medicine.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
